Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuM195 and Chemotherapy for APL in Remission
NCT00002609Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 1994
- Primary completion
- Feb 2003
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lintuzumab in acute promyelocytic leukemia (APL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Antileukemic effects against minimal residual disease. Started Aug 1994; status: completed.
02
Drugs
lintuzumab
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT00002609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002609.